ライフサイエンスコーパス: secondary prevention

1 to prevent new episodes of thrombosis ("pure secondary prevention").

2 older adults with already impaired function (secondary prevention).

3 on of and nonadherence to statin therapy for secondary prevention.

4 ning is common, providing an opportunity for secondary prevention.

5 potential implications in CRC screening and secondary prevention.

6 placebo-controlled trial of pioglitazone for secondary prevention.

7 ure combinations could facilitate its use in secondary prevention.

8 e (ie, cryptogenic), potentially undermining secondary prevention.

9 without comorbidities on statin therapy for secondary prevention.

10 ocardial infarction (MI) is a cornerstone of secondary prevention.

11 r PAD, both for symptomatic patients and for secondary prevention.

12 isk of CVD and receiving effective drugs for secondary prevention.

13 or type of endpoint and in both primary and secondary prevention.

14 festyle programs with regular hospital-based secondary prevention.

15 ent of HE, while seven looked at its primary/secondary prevention.

16 reduction was comparable to that achieved in secondary prevention.

17 nt the implementation of optimal primary and secondary prevention.

18 from 12 trials of aspirin versus control in secondary prevention.

19 n (14%), chronic angina treatment (13%), and secondary prevention (11%) made the largest medical cont

20 III trial, 477 received a defibrillator for secondary prevention; 248 patients were randomly assigne

21 o determine the association between baseline secondary prevention achievement and cardiovascular deat

22 between individual and regional factors and secondary prevention achievement at baseline.

23 addition of ezetimibe to statin therapy for secondary prevention after ACS.

24 stroke prevention in atrial fibrillation and secondary prevention after acute coronary syndromes, pro

25 appropriate adherence to CV medications for secondary prevention after an acute MI.

26 re 4.5% per year overall, 14.0% per year for secondary prevention after cardiac arrest, and 3.1% per

27 implantation of newer-generation DES and in secondary prevention after MI.

28 peutic decision making for vorapaxar use for secondary prevention after MI.

29 as a risk factor requiring intervention for secondary prevention after percutaneous coronary revascu

30 This result may support the importance of secondary prevention after stent implantation.

31 ndomised trials of aspirin versus control in secondary prevention after TIA or ischaemic stroke, we s

32 Aspirin is recommended for secondary prevention after transient ischaemic attack (T

33 will be difficult to deploy, strategies for secondary prevention aimed at later stages of disease ar

34 ucing the rate of unplanned conceptions, and secondary prevention aimed at modification of health beh

35 viously symptomatic patients who had LCSD as secondary prevention, all had an attenuation in cardiac

36 sis in Myocardial Infarction) Risk Score for Secondary Prevention, all patients with DM demonstrated

37 have assessed the role of supplementation in secondary prevention among patients with diabetes mellit

38 rence by 33% compared with usual care in CVD secondary prevention and has been recommended as a "best

39 ally when antithrombotic therapy is used for secondary prevention and is withdrawn perioperatively.

40 ases because of its well-established role in secondary prevention and its widespread availability and

41 In the article by Smith et al, "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Pati

42 ibitors or angiotensin receptor blockers for secondary prevention and treatment of angina doubled, fr

43 assessed in cardiovascular disease patients (secondary prevention) and for two blood pressure ranges

44 ith pre-existing occlusive vascular disease (secondary prevention) and in 500 patients (ie, 5% absolu

45 tations, including acute coronary syndromes, secondary prevention, and clinical angina.

46 ional tests for risk prediction, primary and secondary prevention, and laboratory testing.

47 ional insurance to cover primary prevention, secondary prevention, and tertiary treatment for cardiov

48 finding emphasises the importance of urgent secondary prevention, and the role of stenting for verte

49 rojects will inform the development of novel secondary prevention approaches and underpin the careers

50 tegies to address gaps in lipid lowering for secondary prevention are essential to maximize reduction

51 Although strategies for primary and secondary prevention are well established, their worldwi

52 scents, and children and maintain and target secondary prevention at the population older than 60 yea

53 ditional differentiation between primary and secondary prevention based simply on clinical history.

54 te ischemic stroke are in need of hyperacute secondary prevention because the risk of recurrence is h

55 This suggests that secondary prevention before onset, when beta-cell mass i

56 of death (Ptrend<0.001 for both primary and secondary prevention) but no significant decline in appr

57 (RESPONSE-2: Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2;

58 ministered both as primary prevention and as secondary prevention, by 44% and 52%, respectively.

59 The prevalence of the use of secondary prevention cardiovascular medications is lower

60 ist to improve the quality of cardiovascular secondary prevention care among patients with diabetes m

61 h primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PROVE IT-TIMI 22) with st

62 with no prior cardiovascular event, and the secondary prevention cohort comprised individuals >/=30

63 of UGIB was lower in the primary than in the secondary prevention cohort, numbers needed to harm per

64 nhanced benefit with clopidogrel therapy for secondary prevention compared with aspirin.

65 strategies for studying diseases subject to secondary prevention, comparing the following: 1) CRC ca

66 Medical directors of cardiac rehabilitation/secondary prevention (CR/SP) programs are responsible fo

67 5 (58.4%) primary prevention and 588 (36.7%) secondary prevention devices.

68 d Prevention, efforts to improve primary and secondary prevention effectiveness center on policy deve

69 Primary and secondary prevention efforts should continue to target G

70 Primary and secondary prevention efforts targeted at sexual minority

71 a, a relevant competency gap that influences secondary prevention efforts.

72 For secondary prevention following acute MI, younger age, de

73 y met the primary endpoint for adherence for secondary prevention following an acute MI.

74 Primary prevention exceeds secondary prevention for CHD and pediatrics.

75 VD, including tobacco use, hypertension, and secondary prevention for CVD, will lead to the biggest g

76 Early neurologic evaluation and secondary prevention for stroke are recommended for RAO

77 e failure of homocysteine-lowering trials in secondary prevention from thrombotic vascular events.

78 imary end point event rate was higher in the secondary prevention group compared with the primary pre

79 the treatment effect across the primary and secondary prevention groups.

80 ng copayments for post-myocardial infarction secondary prevention has beneficial effects, but the imp

81 he effectiveness of antiplatelet therapy for secondary prevention has not been defined.

82 Although drug-eluting stents and intensive secondary prevention have contributed to improved outcom

83 ICDs placed for secondary prevention have higher rates of appropriate th

84 Populations include secondary prevention, high-risk primary prevention based

85 ovascular events and benefit from aggressive secondary prevention; however, changes in the use of car

86 he primary (HR, 0.98; 95% CI, 0.74-1.30) and secondary prevention (HR, 0.82; 95% CI, 0.72-0.95) cohor

87 gh-risk (HR: 0.89; 95% CI: 0.83 to 0.95) and secondary prevention (HR: 0.89; 95% CI: 0.83 to 0.96) po

88 gh-risk (HR: 1.11; 95% CI: 0.83 to 1.49) and secondary prevention (HR: 1.08; 95% CI: 0.79 to 1.47) su

89 Registry ICD Registry undergoing first-time secondary prevention ICD implantation between 2006 and 2

90 Secondary prevention ICD recipients aged 18 to 49 (n=114

91 Almost 1 in 5 older patients receiving a secondary prevention ICD survives at least 2 years.

92 ered therapies and outcomes after primary or secondary prevention ICD.

93 1.9 (>/=80 years) per 100 person-years after secondary prevention ICDs (P=0.993).

94 iomyopathy index cases, 44 patients received secondary prevention implantable cardioverter-defibrilla

95 An ICD was implanted for secondary prevention in 10 patients (9.6%) and for prima

96 were primary prevention in 1943 (61.9%) and secondary prevention in 1107 (35.2%).

97 in receptor blocker (ARB) should be used for secondary prevention in all or in only high-risk patient

98 ls comparing anticoagulants with aspirin for secondary prevention in arterial thrombosis and aspirin

99 rtality of older patients receiving ICDs for secondary prevention in contemporary clinical practice.

100 w-dose aspirin may have a continuing role in secondary prevention in HF and underline the need for mo

101 ce the importance of acute clinical care and secondary prevention in improving long-term prognosis of

102 efforts to target early Abeta deposition for secondary prevention in individuals with autosomal domin

103 tations for primary prevention compared with secondary prevention in inherited cardiac diseases.

104 besity paradox have led to uncertainty about secondary prevention in obese patients with stroke.

105 es of bleeding on antiplatelet treatment for secondary prevention in patients of all ages.

106 hough statin medications are recommended for secondary prevention in peripheral arterial disease, the

107 -modifying agents in mild AD patients or via secondary prevention in presymptomatic subjects bearing

108 igh risk inherited arrhythmic conditions and secondary prevention in survivors of sudden cardiac arre

109 527 users of low-dose aspirin for primary or secondary prevention in the Swedish prescription registe

110 y treatments are worthy of consideration for secondary prevention in these patients if ongoing trials

111 Efforts to improve secondary prevention in this population should be focuse

112 lomavirus testing is clinically valuable for secondary prevention in triaging low-grade cytology and

113 Unintended consequences of secondary prevention include potential introduction of b

114 eatment should include guideline-recommended secondary prevention, including antiplatelet and antiath

115 lthough eliminating patient cost sharing for secondary prevention increases adherence and reduces rat

116 -multimineral treatment, used for primary or secondary prevention, increases the risk of mortality in

117 acceptability are low for medicines used in secondary prevention; increasing use is positively relat

118 sease (2 points); renal dialysis (3 points); secondary prevention indication (1 point); and ICD type:

119 Secondary prevention indication (hazard ratio [HR], 3.6;

120 dence interval: 1.87 to 13.14; p < 0.01) and secondary prevention indication (hazard ratio: 6.85; 95%

121 Patients with secondary prevention indication, coronary artery disease

122 ng the importance of longitudinal, sustained secondary prevention initiatives.

123 who might benefit from specific therapies or secondary prevention interventions.

124 Optimal secondary prevention is critical for the reduction of re

125 d be taken into account when the duration of secondary prevention is determined.

126 This therapy, which is sometimes labeled as secondary prevention, is effective in preventing recurre

127 Secondary prevention (maintaining a healthy body weight

128 Aspirin as secondary prevention may be more justified from a risk-b

129 n Follow-up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorecta

130 Ways to better implement secondary prevention measures should be explored in low-

131 Rates of prescription of secondary prevention medication after initial clinic/hos

132 This study assessed practice variations in secondary prevention medication prescriptions among coro

133 re likely to be discharged on evidence-based secondary prevention medication therapies compared with

134 Adherence to key secondary prevention medications (statins, beta-blockers

135 non-STEMI (58% vs 65%), and prescription of secondary prevention medications at discharge.

136 Whether patients receive optimal dosing of secondary prevention medications at the time of and afte

137 s after an AMI are discharged on appropriate secondary prevention medications, dose increases occur i

138 iled to receive their optimal combination of secondary prevention medications.

139 Secondary prevention medicines are unavailable and unaff

140 men) received an S-ICD for primary (n=17) or secondary prevention (n=23 [58%]) at 3 institutions in G

141 with chronic angina (n=33 211) or requiring secondary prevention (n=32 976) in 1999 and 2007 were ex

142 ng signs or symptoms and survival depends on secondary prevention, notably prompt initiation of cardi

143 essful development of new treatments for the secondary prevention of Alzheimer's dementia.

144 outlines current strategies for primary and secondary prevention of anthracycline-induced cardiotoxi

145 Despite the strong evidence for CR in the secondary prevention of ASCVD, it remains vastly underut

146 ase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD.

147 designing early intervention strategies for secondary prevention of asthma.

148 ational studies support statin treatment for secondary prevention of atherosclerotic cardiovascular d

149 ensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular d

150 er high-dose multivitamins are effective for secondary prevention of atherosclerotic disease is unkno

151 standing paradigm supporting aspirin use for secondary prevention of atherothrombotic events.

152 The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

153 The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

154 A2P-TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

155 nts from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

156 s P-TIMI 50 [Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events

157 Data on secondary prevention of cardiovascular disease (CVD) in

158 eview highlights advances in the primary and secondary prevention of cardiovascular disease (CVD) in

159 py, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in

160 ors), commonly prescribed in the primary and secondary prevention of cardiovascular disease, promote

161 role of the antiasthma drug montelukast for secondary prevention of cardiovascular disease.

162 his practice may be clinically useful in the secondary prevention of cardiovascular disease.

163 the use of pharmacological treatment for the secondary prevention of cardiovascular diseases (CVD), s

164 miological and ET studies in the primary and secondary prevention of cardiovascular diseases, particu

165 s of low-dose acetylsalicylic acid (ASA) for secondary prevention of cardiovascular events in a UK pr

166 ing opportunities to improve the primary and secondary prevention of cardiovascular events in Ontario

167 New users of low-dose ASA for secondary prevention of cardiovascular events, aged 50-8

168 e shown that statins help in the primary and secondary prevention of cardiovascular events, not only

169 iency could be beneficial for the primary or secondary prevention of cardiovascular events.

170 data for the role of statins in primary and secondary prevention of cardiovascular events.

171 the mainstay of antiplatelet therapy in the secondary prevention of coronary artery disease.

172 impact of aspirin resistance in primary and secondary prevention of coronary artery disease.

173 e and Pubmed articles related to primary and secondary prevention of CRC and subsequently, a meta-ana

174 225 articles related to primary or secondary prevention of CRC were retrieved.

175 Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism did not res

176 The options for secondary prevention of cryptogenic embolism in patients

177 re seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke.

178 The primary and secondary prevention of CVD is suboptimal throughout the

179 ials of supplementation of EPA+DHA or ALA in secondary prevention of CVD showed no clear benefit.

180 ntinued investment is crucial in primary and secondary prevention of deaths due to congenital abnorma

181 icoagulant rivaroxaban for the treatment and secondary prevention of deep-vein thrombosis and pulmona

182 an expected at all ages, and ineffective for secondary prevention of diarrhea in children <12 mo of a

183 esting direct-acting oral anticoagulants for secondary prevention of embolic strokes of undetermined

184 ure to that of medical therapy alone for the secondary prevention of embolism in patients with patent

185 Evidence-based primary and secondary prevention of HIV using opioid agonist therapi

186 ansfusion is the optimal current therapy for secondary prevention of infarcts for children with SCA a

187 Secondary prevention of injury-related PTS often involve

188 Pioglitazone was effective for secondary prevention of ischemic stroke in nondiabetic p

189 ng the challenges of survivorship, including secondary prevention of long-term morbidity and mortalit

190 rtery disease receive aspirin for primary or secondary prevention of myocardial infarction, stroke, a

191 Further evidence that BPs dispensed for secondary prevention of osteoporotic fractures are not a

192 associated with use of BPs in the setting of secondary prevention of osteoporotic fractures.

193 summarizes guideline recommendations for the secondary prevention of paradoxical embolism.

194 this intervention could also be effective in secondary prevention of prolapse and the need for future

195 ar in childhood and adolescence, primary and secondary prevention of psychiatric disorders offers the

196 DI, but there are few data to support use in secondary prevention of recurrent CDI.

197 ore effective than medical treatment for the secondary prevention of recurrent cerebrovascular events

198 fectiveness of AIT and its potential role in secondary prevention of respiratory allergy progression.

199 resynchronization therapy in the primary and secondary prevention of SCD.

200 Platelets are common targets for primary and secondary prevention of several conditions.

201 All English-speaking participants in the Secondary Prevention of Small Subcortical Strokes (SPS3)

202 eds (CMBs) in lacunar stroke patients in the Secondary Prevention of Small Subcortical Strokes (SPS3)

203 ecent meta-analyses and randomized trials on secondary prevention of squamous cell carcinoma observed

204 stenosis, surgical intervention as a part of secondary prevention of stroke has become widespread.

205 e to assist in the diagnosis, treatment, and secondary prevention of stroke in patients in whom an in

206 tween effects of aspirin and dipyridamole in secondary prevention of stroke.

207 Standard therapy for secondary prevention of strokes and silent cerebral infa

208 table cardioverter-defibrillators (ICDs) for secondary prevention of sudden cardiac death were conduc

209 s; 42% women), who had an ICD for primary or secondary prevention of sudden cardiac death.

210 ice-based therapies for both the primary and secondary prevention of sudden cardiac death.

211 d a class I or IIa indication for primary or secondary prevention of sudden cardiac death.

212 epression and offer a useful strategy in the secondary prevention of the illness.

213 ch biases may be a plausible strategy in the secondary prevention of the illness.

214 antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic events in stable pati

215 of this study is to determine the effect of secondary prevention of vascular events on cognitive fun

216 e may therefore be considered for primary or secondary prevention of vascular events with regard to t

217 roxaban is established for the treatment and secondary prevention of venous thromboembolism, but whet

218 atrial fibrillation and in the treatment and secondary prevention of venous thromboembolism.

219 aspirin with anticoagulants for primary and secondary prevention of venous thrombosis.

220 vices could play a major role in primary and secondary prevention of violence against women.

221 ithin 2 years of randomization or an ICD for secondary prevention of VT/VF within 6 months of randomi

222 us and cardiovascular disease achieved all 5 secondary prevention parameters at baseline, although 71

223 Attainment of 5 secondary prevention parameters-aspirin use, lipid contr

224 mellitus (14 versus 13 years) compared with secondary prevention participants (N=6656; 66%).

225 l-group trial that enrolled 1902 primary and secondary prevention patients (mean [SD] age, 65 [11] ye

226 The rate of appropriate shocks was higher in secondary prevention patients (p < 0.01).

227 erminants of residual risk in statin-treated secondary prevention patients included lipid-related and

228 Conversely, in secondary prevention patients there was a considerably h

229 revention patients and approximately 400,000 secondary prevention patients.

230 rall therapies and shocks in the subgroup of secondary prevention patients.

231 he only trial that enrolled both primary and secondary prevention patients.

232 ascular events independent of clopidogrel in secondary prevention patients.

233 These data suggest that even the secondary prevention population may benefit from program

234 -year risk of recurrent vascular events in a secondary prevention population.

235 n window setting in ICDs in both primary and secondary prevention populations and demonstrates a redu

236 trum of dyslipidemia, event rates similar to secondary prevention populations were observed for patie

237 We examined the impact of a prolonged secondary prevention program on recurrent hospitalizatio

238 treatment, and are unlikely to benefit from secondary prevention recommendations to limit disease pr

239 aspirin use were 601 and 391 for primary and secondary prevention, respectively.

240 an 3.0 years of follow-up, a higher baseline secondary prevention score was associated with improved

241 herapy, vorapaxar administered for long-term secondary prevention significantly reduced ARC definite

242 er results are different during the phase of secondary prevention starting after hospital discharge,

243 Concomitantly, risk factor management and secondary prevention strategies among vascular patients

244 uture studies targeting greater adherence to secondary prevention strategies and novel therapies are

245 es could be leveraged to promote primary and secondary prevention strategies for these infections to

246 ings may warrant further research evaluating secondary prevention strategies in these patients.

247 Intensive primary and secondary prevention strategies may help attenuate this

248 tus for whom closer follow-up and aggressive secondary prevention strategies should be considered.

249 gents and anticoagulants, and greater use of secondary prevention strategies such as statins.

250 Such information will assist in identifying secondary prevention strategies to arrest the atopic mar

251 gh risk of melanoma can optimize primary and secondary prevention strategies.

252 e is, therefore, a key aspect of primary and secondary prevention strategies.

253 trophy may be a feasible outcome measure for secondary prevention studies in asymptomatic amyloidosis

254 Of 3 secondary prevention studies reporting cardiovascular ou

255 Evidence from CVD primary and secondary prevention studies suggested that aspirin ther

256 grade patients were more often implanted for secondary prevention, suffered more often from atrial fi

257 Despite clear evidence of benefit for CAD secondary prevention, the level of risk factor control i

258 ed in addition to statins and other standard secondary prevention therapies appeared effective for th

259 ischemia-producing lesions and intensifying secondary prevention therapies as on the prevention of r

260 Secondary prevention therapies improve longitudinal outc

261 w-up data exist on the impact of appropriate secondary prevention therapies on cognitive function in

262 Rates of medication adherence for secondary prevention therapies ranged from 63.4% to 68.7

263 s (THs) more consistently use evidence-based secondary prevention therapies than non-THs (NTHs).

264 ich was added to standardised cardiovascular secondary prevention therapy.

265 phylactic HPV vaccination; and prospects for secondary prevention through screening for oral HPV infe

266 sterol treatment and control for men, stroke secondary prevention through treatment and control of va

267 supplements to dietary intake and evaluated secondary prevention, thus limiting inference for dietar

268 Urgent action is needed to improve secondary prevention to reduce stroke morbidity and mort

269 lly representative data are sparse regarding secondary prevention treatment and control rates.

270 However, the degree to which secondary prevention treatment goals are achieved in int

271 ded to explore approaches to achieve optimal secondary prevention treatment goals.

272 Clinical trials of secondary prevention treatment in MINOCA patients are la

273 OMega-3 fatty acids (SU.FOL.OM3) trial was a secondary prevention trial (2003-2009; n = 2501) in whic

274 Observational cohort studies and a secondary prevention trial have shown an inverse associa

275 ch 1-mmol/L lower LDL-C level; P = .008) and secondary prevention trials (4.6% lower event rate [95%

276 VTE as a prospective end point in long-term secondary prevention trials evaluating the risks and ben

277 ome a prerequisite for enrollment in several secondary prevention trials for AD, yet the precise effe

278 s may be important for the designs of future secondary prevention trials for Alzheimer disease.

279 Several large-scale Alzheimer disease (AD) secondary prevention trials have begun to target individ

280 Three fairly large secondary prevention trials have not confirmed the previ

281 Secondary prevention trials in AD have already begun in

282 lidating presymptomatic biomarkers now makes secondary prevention trials possible.

283 actors are important to consider in upcoming secondary prevention trials targeting CN individuals at

284 al (CN) individuals is critical for upcoming secondary prevention trials using cognitive outcomes.

285 Randomized controlled primary or secondary prevention trials were considered for inclusio

286 In CVD primary and secondary prevention trials, 20-year CRC mortality was r

287 ritical for the success of recently launched secondary prevention trials.

288 (AD) are increasingly being targeted for AD secondary prevention trials.

289 ese analyses also suggest the feasibility of secondary prevention trials.

290 as been observed with antioxidant therapy in secondary prevention trials.

291 in a primary prevention strategy rather than secondary prevention triggered by acute diarrhea.

292 sis In Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2 degrees P) is a simple 9-poi

293 troke were low and uptake and maintenance of secondary prevention was high.

294 adults with prior cardiovascular disease for secondary prevention was projected to be cost saving in

295 Coverage of primary and secondary preventions was dominated by a strategy of cov

296 r-defibrillator implantation for primary and secondary preventions were retrospectively analyzed.

297 s to prevent the onset of IgE sensitization; secondary prevention, which seeks to interrupt the devel

298 y, and the use of endovascular therapies for secondary prevention, which, so far, have not shown any

299 Among patients with CAD, secondary prevention with a combination of beta-blockers

300 Treating all hypertension for primary and secondary prevention would prevent about 800,000 cardiov